- Market Capitalization, $K 27,869
- Shares Outstanding, K 22,475
- Annual Sales, $ 0 K
- Annual Income, $ -9,240 K
- 60-Month Beta 0.79
- Price/Sales N/A
- Price/Cash Flow N/A
- Price/Book 5.55
|Period||Period Low||Period High||Performance|
| || |
-0.43 (-25.75%)since 08/13/19
| || |
-1.09 (-46.78%)since 06/13/19
| || |
-7.31 (-85.50%)since 09/13/18
Research for the cure for cancer has become this generation's version of President John F. Kennedy's May 25, 1961 proclamation to "Landing a man on the Moon and returning him safely". Much money and effort...
Cancer research has for years been steadily gaining ground on its way to managing, curing and even preventing the various forms of this insidious disease. Both public and private money continues to flow...
Clinical trials are the pathway for new drugs or devices to enter the U.S. and other worldwide markets. However, not all clinical trials are the same. A recent article by a 20+ year insider in the clinical...
Diversifies Seelos' pipeline in rare diseases
-- Unconditional payment of $3.5 million
Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients...
The Barchart Technical Opinion rating is a 100% Sell with a Weakening short term outlook on maintaining the current direction.
Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.
The market is approaching oversold territory. Be watchful of a trend reversal.